Subcutaneous Mosunetuzumab Is Active with a Manageable Safety Profile in Patients (pts) with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphomas (B-NHLs): Updated Results from a Phase I/II Study
暂无分享,去创建一个
L. Sehn | J. Radford | P. Marlton | N. Bartlett | M. Wei | N. Gutiérrez | M. Dreyling | S. Schuster | G. Hess | E. Penuel | M. Matasar | D. Yoon | D. Turner | S. Assouline | K. Fay | E. Budde | P. Giri | S. Yin | Huang Huang | Mingzhu Zhou | S. Yoon | Volker Wiebking | Eva Cybulski